Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Core Insights - Corbus Pharmaceuticals announced data from its first-in-human dose escalation clinical study of CRB-701, which will be presented at the 2025 ASCO GU Symposium in San Francisco from February 13-15, 2025 [1] - The study focuses on CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4 in patients with advanced solid tumors [4][5] Study Details - The Phase 1 study (NCT06265727) consists of three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion) [3] - Part A evaluated four doses: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg administered every three weeks [3] Product Information - CRB-701 (SYS6002) is designed to target Nectin-4, a clinically validated tumor-associated antigen in urothelial cancer, using a site-specific, cleavable linker and a homogeneous drug-antibody ratio of 2 with MMAE as the payload [4] - Corbus has a diversified portfolio that includes CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5]